ACE2 News and Research

RSS

Molecular explanation for increased susceptibility to intestinal inflammation in malnutrition

More than one billion people in poor countries are starving, and malnutrition remains a major problem even in rich countries, making it a leading cause of death in the world. For over a hundred years, doctors have known that a lack of protein in the diet or low levels of amino acids, the building blocks of proteins, can lead to symptoms like diarrhoea, inflamed intestines and other immune system disorders, which weaken the body and can be fatal. However, the molecular mechanism which explains how malnutrition causes such severe symptoms has been largely unexplored.

26 Jul 2012

ACE2 molecule now protects major organs in diabetic patients

ACE2, a molecule that has been shown to prevent damage in the heart, is now proving to be protective of the major organs that are often damaged in diabetic patients.

17 May 2012

Factors of hormone metabolism may make African-Americans more susceptible: Study

High blood pressure also called hypertension is a major health problem that when left untreated can lead to heart disease, stroke and kidney failure. African Americans are more likely to develop high blood pressure and develop it earlier in life than Caucasians. But the reasons for the heightened risk in African Americans still remained largely unknown, although new evidence may provide some insight.

26 Apr 2010

Hundred millions for biotech-licence

Apeiron Biologics AG (Apeiron) today announced the signing of an agreement granting GlaxoSmithKline (GSK) exclusive rights to APN01 (recombinant human Angiotensin Converting Enzyme 2, rhACE2), an enzyme biotherapeutic currently in Phase 1 development for the treatment of the Acute Respiratory Distress Syndrome (ARDS).

3 Feb 2010

Alternative therapy for hypertension

New research from the Northwestern University Feinberg School of Medicine has found that an alternative therapy may be possible for treating some types of hypertension using an enzyme called ACE2.

18 Dec 2009

Ore Pharmaceutical Holdings reports financial results and provides operational updates for third quarter 2009

Ore Pharmaceutical Holdings Inc. today reported financial results and provided an operational update for the third quarter ended September 30, 2009.

13 Nov 2009

Canadian Cardiovascular Society to honor University of Alberta medical researcher

A University of Alberta medical researcher being hailed as a world leader in his field will receive a major national award for his pioneering work in the development of a new class of drugs for the treatment of heart failure.

23 Oct 2009

Regulatory differences between mother and daughter cells shed new light on cell division

When mother and daughter cells are created each time a cell divides, they are not exactly alike. They have the same set of genes, but differ in the way they regulate them. New research now reveals that these regulatory differences between mother and daughter cells are directly linked to how they prepare for their next split.

20 Oct 2009

Efficacy of Ore Pharmaceuticals' lead drug candidate discussed

Ore Pharmaceuticals Inc., announced today the publication of an article in the online version of the journal Inflammation Research titled, “Effects of the ACE2 inhibitor GL1001 on acute dextran sodium sulfate-induced colitis in mice.”

10 Sep 2009

Breakthrough compound could lead to new class of antihypertensive drugs

University of Florida researchers have identified a drug compound that dramatically lowers blood pressure, improves heart function and - in a remarkable finding - prevents damage to the heart and kidneys in rats with persistent hypertension

1 May 2008

Scientists discover the double life of proteins

Scientists at The Australian National University are a step closer to understanding the rare Hartnup disorder after discovering a surprising link between blood pressure regulation and nutrition that could also help to shed light on intestinal and kidney function.

30 Apr 2008

Austrian scientists identify common mechanism underlying acute respiratory disease syndrome

The Spanish flu outbreak of 1918 killed between 30 and 50 million people. In the infected patients, the ultimate cause of death was acute respiratory distress syndrome (ARDS). This fatal condition is a massive reaction of the body during which the lung becomes severely damaged. ARDS can be induced by various bacterial and viral infections, but also by chemical agents.

17 Apr 2008

Discovery of two effective antibodies for SARS

An international team of investigators has identified the first human antibodies that can neutralize different strains of the virus responsible for outbreaks of severe acute respiratory syndrome (SARS).

4 Jul 2007

Researchers detail molecular images of a piece of the spike-shaped protein that the SARS virus uses initiate the first stages of infection

Researchers have determined the first detailed molecular images of a piece of the spike-shaped protein that the SARS virus uses to grab host cells and initiate the first stages of infection.

19 Sep 2005

Blood pressure enzyme linked to SARS virus, could help fight diseases that cause lung failure

Researchers in Austria say that an enzyme that regulates blood pressure is also involved in the SARS virus, and the discovery could lead to new ways of treating diseases that cause lung failure.

11 Jul 2005

Mechanism that prevents kidney damage in the early stages of diabetes associated with obesity

Northwestern University researchers has identified what they believe is a built-in biological mechanism that prevents kidney damage in the early stages of diabetes associated with obesity.

14 May 2004